dr reddy's glp-1 drugs portfolio 2025 Obesity Market With the launch of Obeda®,
Description
Gaucher Disease News: Cerezyme Becomes First FDA-Approved Therapy for Type 3 Gaucher Disease New Treatment for Progressive Pulmonary Fibrosis Lung Disease The FDA approved Boehringer Ingelheims Jascayd (nerandomilast) tablets to treat adults with progressive pulmonary fibrosis (PPF)
After depolarization of presynaptic neurons, acetylcholine is released into the synaptic cleft and binds to postsynaptic receptors such as acetylcholine muscarinic receptors (mAchRs) or acetylcholine nicotinic receptors (nAchRs) (40)
The pathophysiology of this condition is incompletely understood but thought to be related to hypoperfusion of the optic nerve head leading to edema and infarction of optic nerve fibers (87, 88)
The signaling pathway works through interleukin-6 (IL-6) induction
Di Meco A, Curtis ME, Lauretti E, Pratico D
What are the drawbacks of GLP-1s
